TY - JOUR
T1 - Immunohistochemical evaluation of GATA-3 expression in ER-negative breast carcinomas
AU - Liu, Haiyan
AU - Shi, Jianhui
AU - Prichard, Jeffrey W.
AU - Gong, Yun
AU - Lin, Fan
N1 - Publisher Copyright:
© American Society for Clinical Pathology.
PY - 2014/5/1
Y1 - 2014/5/1
N2 - Objectives: Estrogen receptor (ER), gross cystic disease fluid protein 15 (GCDFP-15), and mammaglobin (MGB) are commonly used breast-specific immunomarkers; however, about half of metastatic breast carcinomas are negative for all three. GATA-binding protein 3 (GATA-3) has emerged recently as a sensitive and relatively specific immunomarker for breast and urothelial carcinomas, but the data documenting its expression in ER-negative breast carcinomas are limited; this often poses a dilemma in the setting of metastases. The purpose of this study is to investigate expression of GATA-3 in ER-negative breast carcinomas. Methods: Immunohistochemical evaluation of GATA-3, GCDFP-15, and MGB on 96 ER-negative breast carcinomas was performed. Results: Overall, 69% (66/96), 15% (14/96), and 35% (34/96) of ER-negative breast carcinomas expressed GATA-3, GCDFP-15, and MGB, respectively. Conclusions: Our data suggest that GATA-3 is, so far, the best breast-specific immunomarker, especially when encountering ER-negative metastatic breast carcinomas. GATA-3 should be included in the panel of immunomarkers in the workup of tumors of unknown primary.
AB - Objectives: Estrogen receptor (ER), gross cystic disease fluid protein 15 (GCDFP-15), and mammaglobin (MGB) are commonly used breast-specific immunomarkers; however, about half of metastatic breast carcinomas are negative for all three. GATA-binding protein 3 (GATA-3) has emerged recently as a sensitive and relatively specific immunomarker for breast and urothelial carcinomas, but the data documenting its expression in ER-negative breast carcinomas are limited; this often poses a dilemma in the setting of metastases. The purpose of this study is to investigate expression of GATA-3 in ER-negative breast carcinomas. Methods: Immunohistochemical evaluation of GATA-3, GCDFP-15, and MGB on 96 ER-negative breast carcinomas was performed. Results: Overall, 69% (66/96), 15% (14/96), and 35% (34/96) of ER-negative breast carcinomas expressed GATA-3, GCDFP-15, and MGB, respectively. Conclusions: Our data suggest that GATA-3 is, so far, the best breast-specific immunomarker, especially when encountering ER-negative metastatic breast carcinomas. GATA-3 should be included in the panel of immunomarkers in the workup of tumors of unknown primary.
KW - Breast carcinoma
KW - ER negative
KW - GATA-3
KW - GCDFP-15
KW - Mammaglobin
UR - http://www.scopus.com/inward/record.url?scp=84902577549&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902577549&partnerID=8YFLogxK
U2 - 10.1309/AJCP0Q9UQTEESLHN
DO - 10.1309/AJCP0Q9UQTEESLHN
M3 - Article
C2 - 24713735
AN - SCOPUS:84902577549
SN - 0002-9173
VL - 141
SP - 648
EP - 655
JO - American journal of clinical pathology
JF - American journal of clinical pathology
IS - 5
ER -